StockData
ADMA Biologics, Inc. logo

ADMA Biologics, Inc. (ADMA) stock

ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.63+0.16 (+1.19%)

Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –

ADMA Biologics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

ADMA Biologics's pe ratio was 18.8× on Nov 11, 2026, against 22.6× a year earlier. Over the last 2 years it ranged from 11.7× to 142.8×, with a median of 21.5×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202618.8×−2.6
2025Dec 31, 202521.5×−39.8
2024Dec 31, 202461.3×–

More ADMA Biologics figures

See a number that looks wrong?